

University of Groningen

Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer - Comparison of dose, toxicity and cost-effectiveness

Cheng, Qing; Roelofs, Erik; Ramaekers, Bram L. T.; Eekers, Danielle; van Soest, Johan; Lustberg, Tim; Hendriks, Tim; Hoebbers, Frank; van der Laan, Hans Paul; Korevaar, Erik W.

Published in:
Radiotherapy and Oncology

DOI:
[10.1016/j.radonc.2015.12.029](https://doi.org/10.1016/j.radonc.2015.12.029)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Cheng, Q., Roelofs, E., Ramaekers, B. L. T., Eekers, D., van Soest, J., Lustberg, T., Hendriks, T., Hoebbers, F., van der Laan, H. P., Korevaar, E. W., Dekker, A., Langendijk, J. A., & Lambin, P. (2016). Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer - Comparison of dose, toxicity and cost-effectiveness. *Radiotherapy and Oncology*, 118(2), 281-285. <https://doi.org/10.1016/j.radonc.2015.12.029>

Copyright


Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Particle therapy in head and neck cancer

Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer – Comparison of dose, toxicity and cost-effectiveness



Qing Cheng^{a,1}, Erik Roelofs^{a,1}, Bram L.T. Ramaekers^b, Daniëlle Eekers^a, Johan van Soest^a, Tim Lustberg^a, Tim Hendriks^a, Frank Hoebers^a, Hans Paul van der Laan^c, Erik W. Korevaar^c, Andre Dekker^a, Johannes A. Langendijk^c, Philippe Lambin^{a,*}

^a Department of Radiation Oncology (MAASTRO Clinic), GROW – School for Oncology and Developmental Biology, Maastricht University Medical Center; ^b Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Center; and ^c Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, The Netherlands

ARTICLE INFO

Article history:

Received 22 May 2015

Received in revised form 1 December 2015

Accepted 5 December 2015

Available online 26 February 2016

Keywords:

Proton therapy

Decision support system

Quantitative comparison

Mean dose extraction

Toxicity prediction

Cost-effectiveness estimation

ABSTRACT

To quantitatively assess the effectiveness of proton therapy for individual patients, we developed a prototype for an online platform for proton decision support (PRODECIS) comparing photon and proton treatments on dose metric, toxicity and cost-effectiveness levels. An evaluation was performed with 23 head and neck cancer datasets.

© 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 118 (2016) 281–285
This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Due to the continuous development of new cancer treatments and the sophistication of existing radiotherapy, it has become increasingly challenging to identify the best treatment for a specific patient [1]. A multifactorial clinical decision support system (CDSS) could help meet this challenge when combining clinical, dosimetric and cost variables (e.g. information about the patient or tumour) with expert knowledge (e.g. on a specific treatment modality) to make a quantitative treatment comparison [2–7]. Such a tool would facilitate individualised radiotherapy treatment.

Given its favourable dose distribution, proton therapy is expected to be less toxic and more effective than photon therapy [8–10]. As a result, many oncology centres around the world have introduced proton therapy over the last decade [11]. However, planning studies show that not all patients would benefit from this more expensive treatment [12,13]. Clinical data-exchange platforms have been developed previously to justify patient stratification for a fair and efficient use of the treatment [14–16]. However,

its cost-effectiveness compared to conventional photon radiotherapy is yet unevaluated for many cancers [17–19].

Dutch health authorities have agreed upon the need for a model-based indication methodology to select patients eligible for proton radiotherapy [20–22]. Supplementary Fig. 1 illustrates a Dutch decision tree regarding proton therapy reimbursement. It determines whether a patient is expected to benefit sufficiently from proton therapy justifying reimbursement of the treatment costs. For an effective and efficient evaluation of these aspects, a CDSS is needed that supports the claim whether or not proton therapy is expected to have a clinical benefit in a given patient.

We postulate that such a CDSS should have at least three levels. The first *dosimetric level* should evaluate whether a radiotherapy plan meets predefined dosimetric threshold for a patient's organs at risk (OARs). The second *toxicity level* should estimate whether the probability of radiation induced normal tissue toxicity for the patient is different between different treatment plans. The third *cost-effectiveness level* should evaluate if the extra costs for a certain increase in effectiveness does not exceed a threshold set by society. The effectiveness is defined in quality-adjusted life years (QALYs), which are calculated by estimating the quality and quantity of life extended by a medical intervention [23].

* Corresponding author at: Department of Radiation Oncology (MAASTRO), GROW, Maastricht University Medical Centre, Dr. Tanslaan 12, NL-6229 ET Maastricht, The Netherlands.

E-mail address: philippe.lambin@maastro.nl (P. Lambin).

¹ These authors have had an equal contribution to the manuscript.

To this end, we developed an online, three-level photon vs. proton CDSS prototype named PRODECIS (PROton DECision Support). In this study, we evaluated the system's performance for patients with head and neck cancer (HNC). Data are provided online on www.cancerdata.org [24].

Materials and methods

We designed a modular CDSS (Fig. 1) to support the decision between proton and photon therapy. The system was implemented in Java SE 7 (Oracle, Redwood Shores, CA, USA) and Matlab 2010b (Mathworks, Natick, MA, USA) and designed to import photon and proton treatment plans in DICOM-RT format. A PHP webform was created to upload the data and additionally ask for clinical parameters of the complication models. All patient information and results were anonymously stored in a MySQL Workbench 6.0 (Oracle, Redwood Shores, CA, USA) database.

Computation services were separated into three levels. On the dosimetric level, we adopted in-house dose-volume histogram (DVH) metrics calculation algorithms to extract mean doses from both photon and proton plans. On the toxicity level, we used a number of validated late toxicity prediction models using the TRIPOD Type 4 standard [25] (e.g., regression models [23,26,27]). On the cost-effectiveness level, we incorporated published Markov models¹ [23] to assess the QALY and costs of the treatment.

Experimental setup

To test the system, we used datasets from a ROCOCO cohort of 25 HNC patients for whom both photon and proton plans were available [13]. First, on the dosimetric level we computed the dose to the supraglottis area, the superior pharyngeal constrictor muscle (PCM), and the ipsi- and contralateral parotid glands. Then, on the toxicity level we estimated the normal tissue complication probability (NTCP) for xerostomia and swallowing dysfunction at 6 and 12 months after therapy, using the models published in previous work [23,26,27]. Since the parotid gland location was indicated with left or right in the given datasets, we defined the ipsi- and contralateral parotid glands as receiving higher or lower doses, respectively. Finally, on the cost-effectiveness level we used a Markov model constructed for HNC patients [23] with pre-treatment RTOG grade 2-swallowing dysfunction and xerostomia. The model is described in [Supplementary Table 1](#).

Threshold definition

For the purpose of treatment comparison, we collected various thresholds to define clinical benefit. On the dose comparison level, from expert opinions and literature, we defined a clinical benefit when a plan met clinical, desirable OAR mean dose thresholds being parotid gland <26 Gy, superior PCM <50 Gy and supraglottis area <50 Gy [28–30].

On the toxicity level, based on the CTCAEv4.0 toxicity criteria, we considered clinical benefit as a predicted reduction in probability of grade 2+ toxicity of >10%. In addition, we used the definition of a "complication profile" where, for each patient, the toxicity probability reductions exceeding 5% were summed and clinical benefit was set at a total reduction of 15% or more [31].

On the cost-effectiveness level, we set the acceptable cost per additional QALY derived from the Markov model at €80,000. This is the official threshold proposed in the Netherlands by the Dutch Council for Public Health and Care [32].

Statistics

We used two-tailed Wilcoxon signed rank tests to determine whether the differences between plans were significant. *P*-values of less than 0.05 were considered significant.

Results

System development

The PRODECIS prototype was successfully built on a pipelined image processing framework [33] from within our institute. For scaling purposes, each level of computations was encapsulated into a module and was then installed identically in two parallel pipelines (A and B in Fig. 1). After the whole plan of a treatment was transferred, the respective pipeline began computing. Once both computation pipelines were done, the results were delivered to the third pipeline, comparing the multilevel results with the defined threshold per level. Finally, the comparison results were emailed back to the user. From the 25 datasets, the calculations did not succeed for two, due to DICOM compatibility issues. For every patient, it took approximately five minutes for a computer with standard specifications (Intel® Core™ i5-3210M CPU processor with 2.5 GHz, 4 GB memory) to finish all given tasks.

Experiment results

The system proved successful in the automatic evaluation of proton treatment eligibility according to the model-based approach and predefined thresholds. The number of cases where proton therapy ranked higher as well as average outcomes for both modalities are summarised in [Supplementary Table 2](#). In Fig. 2, the individual results are shown for toxicity and cost-effectiveness, relative to the defined thresholds.

On the dosimetric level, proton therapy significantly lowered doses to the OARs, except for the superior PCM. For the latter, only the proton plans stayed below the thresholds for 2 cases, whereas these were 4, 5 or 12 when considering the supraglottis area, ipsi- or contralateral glands, respectively.

On the toxicity level, proton therapy significantly reduced all toxicities. On average, the probability of swallowing dysfunction 6 months after treatment was reduced from 37% to 28% and from 23% to 18% at 12 months. The probability of xerostomia was reduced for all 23 cases after treatment: from 48% to 25% at 6 months and from 46% to 23% at 12 months. With combined toxicity thresholds, protons outperformed photons for 23 cases at 6 months and 21 cases at 12 months.

On the cost-effectiveness level, we observed an increase in QALY for all the patients in their proton therapy plans, although it was also significantly more expensive. Using the nationally accepted criterion of €80,000 per QALY gained, proton therapy was found to be cost-effective for 8 of the 23 patients.

Discussion

We successfully developed and evaluated the PRODECIS prototype to comply with the Dutch model and added the option to evaluate cost-effectiveness. The study shows that, given nationally accepted guidelines for 15% reduction of a complication profile including swallowing dysfunction and xerostomia, all patients would benefit from proton therapy after 6 months and 91% after 12 months, while 35% would be considered cost-effective at a threshold of 80,000€ per gained QALY. Although a CDSS was previously applied [34,35], we have not found any application that could make quantitative decision-making about photon vs. proton therapy at three levels.

¹ Available on www.predictcancer.org.




Fig. 1. A visualisation of the pipeline system which consists of 3 major pipelines.




Fig. 2. Relative (to threshold of 15%) “complication profiles” after 12 and 6 months (left axis). Only complication predictions that were larger than 5% were included. Right axis for relative (to threshold of €80,000) ICER ($=\Delta\epsilon/\Delta QALY$).

A key characteristic of the system is its parallel pipeline structure, which allows easy extension by reusing the modular code. Another important feature is the dynamic selection of models based on the tumour type. Such flexibility enables the system to rapidly adapt to different user requests and incorporate new insights from the oncology society. Provided the availability of relevant prediction models, future studies could perform systematic experiments to search for an optimal outcome among multiple treatment options at any anatomical site. The third system feature is its use of the Markov model. It consists of health stages in terms of toxicity RTOG grade and translates toxicity probabilities into transitions between health stages (Supplementary Fig. 2). Through the transition of a patient’s health state after treatment, the model estimates the costs and effects of the treatment. An adapted version, referred to as *micro-simulation*, was developed to predict survival of patients with non-small-cell lung cancer [36]. A recently published study [37] shows the same approach to estimate cost-effectiveness of the use of spacers when treating prostate cancer.

Multiple advantages of using the PRODECIS CDSS are foreseen. First, it provides the opportunity for a clinician to make a model-based decision following the Dutch guidelines. Second, it allows clinics to quantitatively prioritise the limited treatment slots and allocate them to the patients expected to gain the most from pro-

ton therapy [17,38]. Third, it quantifies clinical evidence for health insurance policy development. Furthermore, it can help in evaluating the cost-effectiveness of deploying a new technology. A final point to note is that consent for data-exchange to the proposed online system can readily be asked from the patient who is being considered for proton therapy and has a direct benefit of the reuse of its data.

However, these advantages will only be achieved when the following concerns are addressed sufficiently. As the system is still in an early stage, extension to a fully operational system offering user management is required to account for audit trails, for instance. As with the MISTIR platform, security measures for encrypted data transfer are to be provided [14]. Furthermore, the system offers a single-shot evaluation and currently lacks proper case management to retrieve previous comparison outcomes for re-evaluation.

Similar to the ReCompare system [15], the PRODECIS platform is targeted towards referring photon therapy centres, accepting previously calculated photon treatment plans for comparisons. However, PRODECIS also uses user-provided proton plans, whereas ReCompare uses the proton plan generated by the operating proton therapy centre (PTC) itself. Such service can optionally be provided by the staff backing PRODECIS, but as the comparison is performed automatically using standardised models and thresholds an inde-

pendent evaluation of plan quality and prediction of complication rates is offered to other PTC's as well.

A prerequisite for the automatic numerical evaluation of PRODECIS is that the uploaded treatment plans should adhere to strict protocols, specifying contours per tumour group. The use of so-called "umbrella protocols" and international naming convention guidelines will facilitate data exchange in a reusable fashion [39–42]. Although quality assurance methods are implemented, such as contour name mapping, major violation of the protocol will prohibit evaluation, requiring corrections by the user.

It is foreseen that with current efforts from both community as well as industry, instead of calculations based on user-provided treatment plans, automatic plan generation could be applied [43,44]. As an alternative to automatic planning, the estimation of DVH parameters might be reliable and fast, given a sufficiently large historical database of patients with the best planning (as in the study of photon therapy plan optimisation [45]). Patient-selection using a comprehensive matching mechanism based on essential patient characteristics including clinical aspects, tumour location and organ distribution is considered to be incorporated into the PRODECIS system as shown in [Supplementary Fig. 3](#). This will greatly improve the workflow, avoiding the resource-intensive bottleneck of double treatment planning.

A critical factor of the model-based selection method is the quality of the treatment plans under evaluation. Therefore, we expect realistic clinical-grade (thus not "beyond-state-of-the-art") treatment plans that would be administered to the patient in real practice. This means planning protocols need to be up-to-date and in line with the technical possibilities of the treatment options. As for the experiment, the published proton plans for 25 HNC patients are not considered as current standard anymore. We have now produced robust treatment plans (unpublished data), which produce not dramatically different but more realistic proton plans, where in some cases the differences are clinically relevant. To further evaluate the system, we will experiment with external datasets from different centres using different treatment techniques.

Furthermore, in the current prototype, the system only considered those toxicities for which reliable NTCP-models were available and that connected to the cost-effectiveness model. Additional models can easily be added including more OARs such as oral cavity, brainstem, or area postrema to predict acute and late radiation-induced toxicities, which may likely be reduced by proton therapy as well and could mean that the cost-effectiveness of protons will be underestimated. For instance, the first comparison of IMRT versus IMPT among oropharyngeal cancer patients treated with chemo-radiation in the MD-Anderson Cancer centre [46] showed a significant decrease of required tube feeding during the course of radiation when IMPT was used. In this regard, direct measurement of QALY's in prospective data registration programs is needed to obtain better insight into the cost-effectiveness of protons. In addition, to maximise system utility, it is highly desirable to use toxicity models that consider multiple stages. e.g. A reduction of grade 4–5 toxicities is of utmost clinical benefit, but the number of patients is too low to train such a model reliably, which requires international data pooling or rather distributed learning systems [47–49].

The HNC Markov model adopted in this system depended on acceptable costs, which vary from country to country and even from hospital to hospital. It also depended on toxicity estimation models that were regressed without patients' biomedical data. Furthermore, previous interventions such as surgery or chemotherapy were not included in the system, which will bias the complication predictions. Therefore, service at this level is a proof of principle and not conclusive.

The next step will be to include genetic biomarkers of radio-sensitivity to further improve the prediction of late toxicities

[50,51]. We aim to continuously update the system with additional models that apply to other diseases and are scalable to other countries. Finally, patient-specific data such as molecular information, patient-reported outcomes and personal preference should be incorporated to truly improve the level of personalisation in decision support systems.

Conflict of interest

None.

Acknowledgments

We thank MAASTRO's software development team for their support. Furthermore, we acknowledge the involvement of colleagues from the clinic's departments, the data management team and treatment planning. The authors acknowledge financial support from the EU 7th framework programme (ARTFORCE – no. 257144, REQUITE – no. 601826), an NGI Pre-Seed Grant (no. 93612005) and Kankeronderzoekfonds Limburg from the Health Foundation Limburg.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.radonc.2015.12.029>.

References

- [1] Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruyscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. *Radiother Oncol* 2010;95:32–40.
- [2] Lambin P, Roelofs E, Reymen B, et al. Rapid Learning health care in oncology – an approach towards decision support systems enabling customised radiotherapy. *Radiother Oncol* 2013;109:159–64.
- [3] Pijls-Johannesma M, Grutters JP, Verhaegen F, Lambin P, De Ruyscher D. Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review. *Oncologist* 2010;15:93–103.
- [4] Peeters A, Grutters JP, Pijls-Johannesma M, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. *Radiother Oncol* 2010;95:45–53.
- [5] Lambin P, Petit SF, Aerts HJ, The ESTRO, Lecture Breur, et al. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. *Radiother Oncol* 2009;2010:145–52.
- [6] Lambin P, van Stiphout RG, Starmans MH, et al. Predicting outcomes in radiation oncology—multifactorial decision support systems. *Nat Rev Clin Oncol* 2013;10:27–40.
- [7] Lambin P, Zindler J, Vanneste B, et al. Modern clinical research: how rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. *Acta Oncol* 2015:1–12.
- [8] Proton radiotherapy. Horizon scanning report. Health Council of the Netherlands, 2009. Available from: http://www.gezondheidsraad.nl/sites/default/files/summary_200917.pdf.
- [9] Pijls-Johannesma M, Grutters JP, Lambin P, Ruyscher DD. Particle therapy in lung cancer: where do we stand? *Cancer Treat Rev* 2008;34:259–67.
- [10] Grutters JP, Abrams KR, de Ruyscher D, et al. When to wait for more evidence? Real options analysis in proton therapy. *Oncologist* 2011;16:1752–61.
- [11] Jermann M. Particle therapy statistics in 2014. *Int J Part Ther* 2015;2:50–4.
- [12] Roelofs E, Engelsman M, Rasch C, et al. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. *J Thorac Oncol* 2012;7:165–76.
- [13] van der Laan HP, van de Water TA, van Herpt HE. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: a planning comparative study. *Acta Oncol* 2013;52:561–9.
- [14] Roelofs E, Persoon L, Qamhiyeh S, et al. Design of and technical challenges involved in a framework for multicentric radiotherapy treatment planning studies. *Radiother Oncol* 2010;97:567–71.
- [15] Lühr A, Lock S, Roth K, et al. Concept for individualized patient allocation: ReCompare—remote comparison of particle and photon treatment plans. *Radiat Oncol* 2014;9:59.

- [16] Lock S, Roth K, Skripcak T, et al. Implementation of a software for REmote COMparison of PARTicle and photon treatment plans: ReCompare. *Z Med Phys* 2015;25:287–94.
- [17] Bekelman JE, Asch DA, Tochner Z, et al. Principles and reality of proton therapy treatment allocation. *Int J Radiat Oncol Biol Phys* 2014;89:499–508.
- [18] Pijls-Johannesma MC, de Ruyscher DK, Dekker AL, Lambin P [Protons and ions in the treatment of cancer; a systematic review of the literature]. *Ned Tijdschr Geneesk* 2006;150:2435–41.
- [19] Grutters JP, Pijls-Johannesma M, Ruyscher DD, et al. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. *Cancer Treat Rev* 2010;36:468–76.
- [20] Langendijk JA, Lambin P, De Ruyscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. *Radiother Oncol* 2013;107:267–73.
- [21] Widder J, van der Schaaf A, Lambin P, et al. The quest for evidence for proton therapy: the model-based approach and precision medicine. *Int J Radiat Oncol Biol Phys* 2015.
- [22] Grau C. The model-based approach to clinical studies in particle radiotherapy—a new concept in evidence based radiation oncology? *Radiother Oncol* 2013;107:265–6.
- [23] Ramaekers BL, Grutters JP, Pijls-Johannesma M, Lambin P, Joore MA, Langendijk JA. Protons in head-and-neck cancer: bridging the gap of evidence. *Int J Radiat Oncol Biol Phys* 2013;85:1282–8.
- [24] Cheng Q, Roelofs E, Ramaekers B, et al. Data from: development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer – comparison of dose, Toxicity and Cost-Effectiveness. *Cancer Data* 2015. <http://dx.doi.org/10.17195/candat.2015.10.5>.
- [25] Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *Eur J Clin Invest* 2015;45:204–14.
- [26] Christianen ME, Schilstra C, Beetz I, et al. Predictive modelling for swallowing dysfunction after primary (chemo)radiation: results of a prospective observational study. *Radiother Oncol* 2012;105:107–14.
- [27] Beetz I, Schilstra C, Burlage FR, et al. Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors. *Radiother Oncol* 2012;105:86–93.
- [28] Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose–volume effects on salivary gland function. *Int J Radiat Oncol Biol Phys* 2010;76:S58–63.
- [29] Rancati T, Schwarz M, Allen AM, et al. Radiation dose–volume effects in the larynx and pharynx. *Int J Radiat Oncol Biol Phys* 2010;76:S64–69.
- [30] Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose–effect relationship. *Radiother Oncol* 2007;85:64–73.
- [31] Consensus document voor selectie van patiënten met een model-based indicatie voor protonen therapie (Unpublished internal document). Landelijk Platform Protonen Therapie (LPPT), 2015.
- [32] Sensible and sustainable care. Council for Public Health and Care (RVZ), 2006. Available from: http://www.raadrvs.nl/uploads/docs/Sensible_and_sustainable_care.pdf.
- [33] Van Soest J, Lustberg T, Grittner D, et al. Towards a semantic PACS: using Semantic Web technology to represent imaging data. *Stud Health Technol Inform* 2014;205:166–70.
- [34] Seroussi B, Soulet A, Messai N, Laouenan C, Mentre F, Bouaud J. Patient clinical profiles associated with physician non-compliance despite the use of a guideline-based decision support system: a case study with OncoDoc2 using data mining techniques. *AMIA Annu Symp Proc* 2012;2012:828–37.
- [35] Steele SR, Bilchik A, Johnson EK, et al. Time-dependent estimates of recurrence and survival in colon cancer: clinical decision support system tool development for adjuvant therapy and oncological outcome assessment. *Am Surg* 2014;80:441–53.
- [36] Bongers ML dRD, Oberije C, Lambin P, Uyl-de Groot CA, Belderbos J, Coupé VHM. Calibration of a micro-simulation model to assess cost-effectiveness of conventional and innovative chemoradiation schemes in non-small cell lung cancer In process.
- [37] Vanneste BG, Pijls-Johannesma M, Van De Voorde L, et al. Spacers in radiotherapy treatment of prostate cancer: is reduction of toxicity cost-effective? *Radiother Oncol* 2015;114:276–81.
- [38] Jakobi A, Bandurska-Luque A, Stutzer K, et al. Identification of patient benefit from proton therapy for advanced head and neck cancer patients based on individual and subgroup normal tissue complication probability analysis. *Int J Radiat Oncol Biol Phys* 2015;92:1165–74.
- [39] CancerData.org. EuroCAT Umbrella Protocol for NSCLC 2015 [cited 2015 6 Oct]. Available from: <https://www.cancerdata.org/protocols/eurocat-umbrella-protocol-nsclc>.
- [40] Meldolesi E, van Soest J, Dinapoli N, et al. An umbrella protocol for standardized data collection (SDC) in rectal cancer: a prospective uniform naming and procedure convention to support personalized medicine. *Radiother Oncol* 2014;112:59–62.
- [41] Melidis C, Bosch WR, Izewska J, et al. Global harmonization of quality assurance naming conventions in radiation therapy clinical trials. *Int J Radiat Oncol Biol Phys* 2014;90:1242–9.
- [42] Santanam L, Hurkmans C, Mutic S, et al. Standardizing naming conventions in radiation oncology. *Int J Radiat Oncol Biol Phys* 2012;83:1344–9.
- [43] Voet PW, Dirckx ML, Breedveld S, Fransen D, Levendag PC, Heijmen BJ. Toward fully automated multicriterial plan generation: a prospective clinical study. *Int J Radiat Oncol Biol Phys* 2013;85:866–72.
- [44] Kraan AC, van de Water S, Teguh DN. Dose uncertainties in IMPT for oropharyngeal cancer in the presence of anatomical, range, and setup errors. *Int J Radiat Oncol Biol Phys* 2013;87:888–96.
- [45] Petit SF, Wu B, Kazhdan M, et al. Increased organ sparing using shape-based treatment plan optimization for intensity modulated radiation therapy of pancreatic adenocarcinoma. *Radiother Oncol* 2012;102:38–44.
- [46] Frank SJ, Rosenthal DI, Ang K, et al. Gastrostomy Tubes Decrease by Over 50% With Intensity Modulated Proton Therapy (IMPT) During the Treatment of Oropharyngeal Cancer Patients: A Case-Control Study. Proceedings of the American Society for Radiation Oncology 55th Annual Meeting ASTRO's 55th Annual Meeting 2013;87.
- [47] Deasy JO, Bentzen SM, Jackson A, et al. Improving normal tissue complication probability models: the need to adopt a “data-pooling” culture. *Int J Radiat Oncol Biol Phys* 2010;76:S151–154.
- [48] Dekker A, Nalbantov G, Oberije C, et al. Multi-centric learning with a federated IT infrastructure: application to 2-year lung-cancer survival prediction. *Radiother Oncol* 2013 Mar;106:S193.
- [49] Skripcak T, Belka C, Bosch W, et al. Creating a data exchange strategy for radiotherapy research: towards federated databases and anonymised public datasets. *Radiother Oncol* 2014;113:303–9.
- [50] Fachal L, Gomez-Caamano A, Barnett GC, et al. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. *Nat Genet* 2014;46:891–4.
- [51] Barnett GC, Thompson D, Fachal L, et al. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. *Radiother Oncol* 2014;111:178–85.